Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20070139 | 0.90 | RET (0.40) | RETOPRK1DRD2SSTR4DPP7 | |
| SCHEMBL20205833 | 0.89 | RET (0.39) | RETOPRK1DRD2SSTR4DPP7 | |
| SCHEMBL20147500 | 0.85 | RET (0.38) | RETOPRK1DRD2SSTR4DPP7 | |
| SCHEMBL21651988 | 0.83 | RET (0.37) | RETOPRK1DRD2SSTR4DPP7 | |
| SCHEMBL20626703 | 0.83 | RET (0.40) | RETOPRK1DRD2SSTR4DPP7 | |
| SCHEMBL12282454 | 0.67 | HSD11B1 (0.50) | DRD2SSTR4 | |
| SCHEMBL21651960 | 0.66 | RET (0.41) | RETDRD2 | |
| SCHEMBL20158493 | 0.65 | RET (0.44) | RETDRD2 | |
| SCHEMBL20069523 | 0.64 | RET (0.44) | RET | |
| SCHEMBL21651931 | 0.64 | RET (0.45) | RETDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885OPRK1 2369/4885DRD2 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.